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Background: The acupuncture or electroacupuncture (EA) shows the therapeutic effect on various neurodegenerative
diseases. This effect was thought to be partially achieved by its ability to alleviate existing neuroinflammation and glial
dysfunction. In this study, we systematically investigated the effect of EA on abnormal neurochemical changes and
motor symptoms in a mouse neurodegenerative disease model.
Methods: The transgenic mouse which expresses a mutant α-synuclein (α-syn) protein, A53T α-syn, in brain astrocytic
cells was used. These mice exhibit extensive neuroinflammatory and motor phenotypes of neurodegenerative
disorders. In this study, the effects of EA on these phenotypic changes were examined in these mice.
Results: EA improved the movement detected in multiple motor tests in A53T mutant mice. At the cellular level,
EA significantly reduced the activation of microglia and prevented the loss of dopaminergic neurons in the
midbrain and motor neurons in the spinal cord. At the molecular level, EA suppressed the abnormal elevation of
proinflammatory factors (tumor necrosis factor-α and interleukin-1β) in the striatum and midbrain of A53T mice.
In contrast, EA increased striatal and midbrain expression of a transcription factor, nuclear factor E2-related factor
2, and its downstream antioxidants (heme oxygenase-1 and glutamate-cysteine ligase modifier subunits).
Conclusions: These results suggest that EA possesses the ability to ameliorate mutant α-syn-induced motor
abnormalities. This ability may be due to that EA enhances both anti-inflammatory and antioxidant activities and
suppresses aberrant glial activation in the diseased sites of brains.
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As a conventional cytosolic protein, α-synuclein (α-syn),
has been assumed to exert its pathogenic function exclu-
sively in the cytoplasm in a cell-autonomous manner [1].
However, this view has been challenged by the presence
of α-syn and its aggregated forms in the extracellular
fluid such as cerebrospinal fluid and blood plasma of
both Parkinson’s disease (PD) and normal subjects [2, 3].
Although the mechanisms underlying α-syn secretion
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unless otherwise stated.fibrils are released to the extracellular environment by
non-classical exocytosis [4, 5]. Extracellularly misfolded α-
syn can propagate in a prion-like spreading fashion [6, 7]
and be endocytosed by neighboring neurons or glia [8],
through which α-syn spreads and amplifies degenerative
signals from cells to cells [9].
Glial cells are particularly involved in cell-to-cell con-
tacts of α-synucleinopathies in the progression of neuro-
degenerative disorders [10]. Several lines of evidence
have shown that α-syn-containing inclusion bodies ag-
gregated in astrocytes and oligodendrocytes in PD, de-
mentia with lewy bodies, and multiple system atrophy
[11–13]. In fact, α-syn-positive inclusions have been ob-
served in astrocytes and oligodendrocytes in the sub-
stantia nigra (SN) and/or locus coeruleus of postmortemhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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was related to the progress of PD [14]. However, the
underlying mechanisms for α-synucleinopathies in glia
and its roles in disease onset and progression remain
unclear.
An experimental α-syn-inducible transgenic mouse, in
which PD-related A53T mutant α-syn is selectively
expressed in astrocytes, developed an early-onset, rapidly
progressed movement disability. Increasing astrocytic α-
syn deposition initiated widespread astrogliosis, micro-
glial activation, and dopaminergic neuronal degeneration
[15]. It appears that α-syn induces early astrocytic dys-
function and severe inflammation responses, which ac-
celerate neuronal damage and PD progression [10]. In
addition, α-syn is released from neuronal cells, and the
released α-syn is readily endocytosed by astrocytes, lead-
ing to neuroinflammatory responses [16]. Therefore, re-
storing glial function and inhibiting microglial activation
are of therapeutic benefit for treating PD [17].
Due to severe side effects induced by long-term medica-
tions for treating chronic neurodegenerative diseases, it is
necessary to find non-pharmacological tools to ameliorate
these disorders. Acupuncture or electroacupuncture (EA)
represents a non-invasive procedure and has long been
used to relieve pain and promote stroke rehabilitation
[18, 19]. Several neurodegenerative disorders, such as
amyotrophic lateral sclerosis [20], ischemia [21], and
PD [22, 23], are also seemingly suitable for EA treat-
ment. Although the use of EA has been endorsed by
the US National Institutes of Health and the World
Health Organization, and the anti-inflammatory effect
of acupuncture has been well documented in human
and animal studies [24–27], little is understood about
its biochemical basis for therapy.
In this study, we attempted to investigate the neuro-
chemical basis for the therapeutic effect of EA. To this
end, we used a transgenic mouse line which was con-
structed to selectively express α-syn A53T mutant in
astrocytic cells. The anti-inflammatory effect of EA was
investigated in these mice. The effects of EA on motor
behavior and activities of glial and neuronal cells were
also examined. In addition, the nuclear factor E2-related
factor 2 (Nrf2)-antioxidant response element (ARE) sig-
naling pathway, a key mediator in oxidative stress and
inflammation [28], was analyzed for its responses to EA.
Methods
Animals
TetO-A53T mice, tetracycline operator (tetO)-regulated
α-syn transgenic mice, and glial fibrillary acidic protein
(GFAP)-tTA mice (GFAP promoter-controlled tetracyc-
line transactivator transgenic mice) were obtained from
Prof. Huaibin Cai’s laboratory in the National Institutes
of Health. These mice were crossed to generate GFAP-tTA/tetO-α-syn (A53T) double transgenic mice. The
mice were housed in a pathogen-free climate-controlled
facility with diet and water available ad libitum. The ani-
mal room was on a 12/12 h light/dark cycle. To assess
the impact of developmental expression of A53T α-syn
on the neurological function, a cohort of A53T mice was
administered with doxycycline (DOX), a tetracycline de-
rivative, to block the expression of A53T α-syn from the
embryonic stage to postnatal day 21 (P21). Genotypes
were determined by polymerase chain reaction (PCR)
analysis of tail DNA [15]. All procedures were approved
by the Ethical Committee for Animal Research of Cap-
ital Medical University.
EA stimulation
Mice were divided into four groups: untreated non-
transgenic (nTg) control, untreated A53T transgenic,
100 Hz EA-treated nTg, and 100 Hz EA-treated A53T
mice. The EA stimulation was given for 4 weeks starting at
2 months of age. Mice were gently handled and lightly re-
strained in a plastic cylinder (7 × 2.5 cm) with their hind
limbs accessible for needling. For this procedure, the mice
were immobilized for 30 min during EA administration
with no anesthetization [29]. After cleaning the skin with
alcohol, two sterilized stainless-steel needles (0.18 mm
diameter × 3 mm length) were inserted in each leg, one at
ST36 (2 mm lateral to the anterior tubercle of tibia) and
the other at SP6 (2 mm proximal to the upper border of
medial malleolus, at the posterior border of the tibia). The
EA performed at these acupoints is known to relieve PD-
like symptoms such as muscle and movement disorders
[30]. The stimuli were generated from a Han’s Acupoint
Nerve Stimulator (HANS, LH series, manufactured in Pe-
king University). Bidirectional square wave electrical pulses
(0.2 ms duration, 100 Hz) designated as EA were given for
a total of 30 min each day. The intensity of the stimulation
at 100 Hz was increased stepwise from 1 to 1.2 mA and
then to 1.4 mA, with each step lasting for 10 min.
Behavioral test
Open-field test
Locomotor activity was assessed in automated activity
chambers (25.4 × 25.4 in. square) connected to a digital
scan analyzer that transmitted the number of infrared
beam breaks (activity data) to a Mouse Tru Scan system
(Truscan 2.0 Instruments, Columbus, USA). Total move-
ment distance (cm) was recorded across a 30-min record-
ing period.
Rotarod test
The length of time a mouse stayed on a rotating rod with
auto acceleration from 0 rotation per minute (rpm) to 40
rpm in 5 min (Acceler ROTA-ROD, Jones & Roberts, CA)
was recorded.
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Mouse forepaws or hindpaws were pulled or compressed
a triangular bar linked to a digital force gauge (San Diego
Instruments, San Diego, CA). The maximal pulling or
compressing force was recorded. The mean of five mea-
surements was analyzed for each animal during each test.
Gait analysis
The Catwalk gait analysis method has been reported in
details [31]. Briefly, mice were placed individually in the
Catwalk walkway system (Noldus Information Technol-
ogy, The Netherlands) and were allowed to walk freely
and traverse from one side to the other of the walkway
glass plate. During the recording, the environment was
kept completely dark, except for the light from the com-
puter screen. Where the mouse paws made contact with
the glass plate, light emitting diode light was reflected
down and the illuminated contact areas were recorded
with a high speed color video camera underneath the glass
plate connected to a computer that run the Catwalk soft-
ware 9.1. Stride length and interlimb coordination mea-
sured as regularity index, which is the percentage of
normal step sequences, were analyzed.
Histology and immunohistochemical analysis
Mice were deeply anesthetized and transcardially per-
fused with saline followed by fixative (4 % paraformalde-
hyde in 0.1 M phosphate buffered saline (PBS), pH 7.4.
Brain and spinal cord tissues were removed and post-
fixed in the same fixative overnight. Following equilibra-
tion in 30 % sucrose in PBS, 30 μm sections were cut in
the coronal plane with a cryostat at −20 °C and proc-
essed for immunohistochemistry. Primary antibodies
against GFAP (1:1000, Sigma-Aldrich USA, St. Louis,
MO), ionized calcium-binding adaptor molecule-1 (Iba1)
(1:1000, Wako Chemicals USA, Richmond, VA), tyrosine
hydroxylase (TH) (1:1000, Sigma-Aldrich USA, St. Louis,
MO), α-syn (C20 & 211, 1:1000, Santa Cruz Biotech,
Santa Cruz, CA), and secondary Alexa 488- or Alex 568-
conjugated antibodies (1:1000, Invitrogen) were used to
visualize the staining. Dapi (1:1000, Invitrogen) was used
for counterstaining the nuclei. A monoclonal mouse
anti-neuronal Nuclei (NeuN) antibody was used at a
1:1000 dilution (Chemicon International, Temecula,
CA). Immunofluorescent images were captured using a
laser scanning confocal microscope (Leica TCS SP8,
Germany).
Stereology
According to stereotaxic coordinates of mouse brains
[32], a series of coronal sections across the substantia
nigra pars compacta (SNpc) (Bregma −2.54 ~ −3.88 mm)
was stained with TH and visualized using the Vectastain
ABC kit (Vector Laboratories, Burlingame, CA). Thenumber of TH-positive cells was assessed using an un-
biased stereological procedure with an optical fractionator
Stereo Investigator (Micro-Bright Field Inc, Williston,
VT). The coefficient of error (CE) was designed less than
10 % in order to get reliable results.
Quantitation of proinflammatory cytokines
We quantified proinflammatory cytokine levels in the
SNpc and striatum. Tissues were homogenized in ice-cold
lysis buffer containing 137 mM NaCl, 20 mM Tris (pH
8.0), 1 % (v/v) glycerol, 1 % (v/v) Nonidet P-40, 1 mM phe-
nylmethylsulfonyl fluoride, and 0.5 mM sodium vanadate.
The homogenate was centrifuged at 1500g for 15 min at
4 °C. The supernatant was collected and stored at −80 °C
before use. The levels of tumor necrosis factor-α (TNF-α)
and interleukin-1β (IL-1β) were detected using mouse
TNF-α and IL-1β enzyme-linked immunosorbent assay
(ELISA) kits (Shanghai ExCell Biology Inc., Shanghai,
China), respectively, according to the manufacturer’s
instructions. The sensitivity of the ELISA assay was 15
pg/ml for both TNF-α and IL-1β. Standards were assayed
in duplicates. The protein concentration was determined
using a detergent compatible protein assay with bovine
serum albumin as the standard.
Western blot
Proteins were separated on 10 % SDS-PAGE gels and elec-
trophoretically transferred to polyvinylidene difluoride
membranes (Millipore). Membranes were blocked with
5 % nonfat dry milk in PBS for 2 h at room temperature
and incubated overnight at 4 °C with a primary anti-
body. Antibodies against α-syn (1:1000, Santa Cruz
Biotech, Santa Cruz, CA), Nrf2 (1:500, Sigma-Aldrich
USA, St. Louis, MO), heme oxygenase-1 (HO-1) (1:300,
Abcam, Cambridge, UK), glutamate-cysteine ligase
modifier subunits (GCLM) (1:500, Abcam, Cambridge,
UK), or β-actin (1:5000, Sigma-Aldrich USA, St. Louis,
MO) were used in this study. The membranes were
then treated with an anti-rabbit or anti-mouse antibody
conjugated with IRDye™ 800 green or IRDye™ 700 red
(Rockland, Limerick, PA) for 1 h. They were washed
three times with PBS containing 0.1 % Tween and twice
with PBS alone. Proteins were visualized by a LI-COR
Odyssey infrared double-fluorescence imaging system
(American Company LICOR).
High-performance liquid chromatography (HPLC)
Samples from striatal tissue were prepared to detect the
DA concentration as previously described [29]. Each sam-
ple was injected into an HPLC system (Model 5600A;
CoulArray Detector System ESA, Brighton, MA) for
analysis. The mobile phase was 0.125 M sodium citrate
buffer containing 20 % methanol, 0.1 mM Na2EDTA,
Deng et al. Journal of Neuroinflammation  (2015) 12:103 Page 4 of 14and 0.5 mM 1-octanesulfonic acid (Acros Organics,
Morris Plains, NJ).
Isolation of total RNA and quantitative real-time PCR
The isolation of total RNA was performed by using an
RNA NucleoSpin® kit according to the manufacturer’s
instructions (Macherey-Nagel, Germany). Reverse tran-
scriptase reactions were run on 1 μg of total messenger
RNA (mRNA) by using ProtoScript M-Mulv First Strand
cDNA Synthesis Kit (New England Biolabs, USA). Quan-
titative PCR was performed by using a Brilliant IISYBR
Green QPCR Master Mix (Agilent Technologies, USA).
The primers sequences were α-synF (5′-TGG ATG TAT
TCA TGA AAG GA-3′), α-synR (5′-CCA GTG GCT
GCT GCA ATG CTC-3′), GFAPF (5′-CGA GTC CCT
AGA GCG GCA AAT G-3′), GFAPR (5′-CGG ATC
TGG AGG TTG GAG AAA GTC-3′), Nrf2/5′ (5′-TTC
TTT CAG CAG CAT CCT CTC CAC-3′), Nrf2/3′ (5′-
ACA GCC TTC AAT AGT CCC GTC CAG-3′), HO-1/
5′ (5′-CAA GCC GAG AAT GCT GAG TTC ATG-3′),
HO-1/3′ (5′-GCA AGG GAT GAT TTC CTG CCA
G-3′), GCLM/5′ (5′-GCC ACC AGA TTT GAC TGC
CTT TG-3′), GCLM/3′ (5′-TGC TCT TCA CGA TGA
CCG AGT ACC-3′), ActinF (5′-CTG GCT CCT AGC
ACC ATG AAG ATC-3′), ActinR (5′-TGC TGA TCC
ACA TCT GCT GG-3′).
Statistical analysis
All data are represented as means ± SEM and were ana-
lyzed by one-way ANOVA or Student’s t test as appropriateFig. 1 EA reduced loss of body weight, delayed paralysis onset, and increa
experimental timeline for behavioral tests and EA treatments. b Effects of E
significant loss of body weight starting at 70 days in A53T mice. EA was able
EA on the onset of paralysis observed in A53T mice (n = 15 per group). d Effe
are expressed as means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. nTg groby using Prism 5.0 software (GraphPad Software,
San Diego, CA). P < 0.05 was considered statistically
significant.Results
EA delayed the early onset of movement disability in
A53T mice
A53T α-syn mice were administered with DOX from
embryonic stages (E0) to P21 to block the developmental
expression of A53T α-syn (Fig. 1a). At day 60 (P60),
A53T or nTg control mice received 4-week EA treat-
ment. Before and after EA treatment, motor behaviors
were examined.
A53T mice displayed a loss of body weight as com-
pared to age-matched nTg mice at 70th day. The body
weight of A53T mice continued to drop during the dis-
ease progression. EA at 100 Hz significantly prevented
the loss of body weight. However, EA had no effect on
the body weight of nTg mice (Fig. 1b). The early-onset
paralysis was also seen in A53T mice which may result
from the significant neuronal loss in the midbrain and
spinal cord [15]. Average age of onset for paralysis devel-
oped with one of four limbs in A53T mice was 92.9 ±
2.3 days. This symptom then quickly spread to other
limbs which eventually caused death of animals at an
average lifespan of 99.4 ± 2.0 days (Fig. 1c, d). Interest-
ingly, 100 Hz EA significantly delayed the average age of
onset to 102.7 ± 2.1 days and prolonged the average life-
span to 108.9 ± 2.3 days (Fig. 1c, d).sed lifespan in A53T mice. a Schematic diagram illustrating the
A on the loss of body weight in A53T mice (n = 10 per group). Note a
to reverse the loss at three testing days (80, 90, and 100 days). c Effects of
cts of EA on survival rate of A53T mice (n = 15 per group). Data in Fig. 1b
up. #P < 0.05, ##P < 0.01 vs. A53T group
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field test was first carried out to assess the spontaneous
locomotor activity in A53T and nTg mice after 4-week EA
treatment. The movement distance was significantly de-
creased in A53T mice (2221.7 ± 160.0 cm) compared to
nTg mice (4145.9 ± 252.3 cm). EA at 100 Hz effectively in-
creased the movement distance (3320.1 ± 211.0 cm)
(Fig. 2a). The motor coordination of A53T mice was de-
creased in a rotarod test, which was partially reversed by
100 Hz EA (Fig. 2b). The grip strength test is a feasible
way to objectively quantify the muscular strength of ro-
dents. The mean grip force in the fore- and hindlimbs of
A53T mice was significantly reduced relative to nTg mice
(Fig. 2c). EA (4 weeks, 100 Hz) restored the mean grip
force by 62.9 and 35.6 % respectively in the fore- and hin-
dlimbs compared to A53T mice without EA (Fig. 2c). InFig. 2 EA improved motor function in A53T mice. a Effects of EA on tota
recorded for 30 min (n = 9 per group). b Effects of EA on the duration of
c Effects of EA on the grip strength of forelimbs and hindlimbs in A53T a
stride length of four limbs in A53T and control mice (n = 6 per group). f
group). Note that EA stimulation generally improved all motor activities s
group. #P < 0.05, ##P < 0.01, ###P < 0.001 vs. A53T groupaddition, Catwalk gait analysis showed a significant de-
crease in stride length of all four paws in A53T mice. One
hundred hertz EA significantly increased its stride length
in the left-fore, left-hind, and right-hind paw although not
the right forelimb (Fig. 2d, e). The interlimb coordination
measured by regularity index in A53T mice was reduced
to 47.7 % of control nTg mice. One hundred hertz EA re-
covered the regularity index by 84.6 % during the course
of the experiment (Fig. 2f). EA had no significant effect on
all motor activities surveyed in nTg mice.
Noticeably, within 2 months of age, EA had a minimal
impact on the motor impairments in movement dis-
tance, latency time, grip force, and Catwalk gait (data
not shown). After 2 months of age, A53T mice showed
an acceleration of the motor disability. At the same time,
EA treatment had its maximal effects. The accelerationl distance in A53T and control mice. Mice in each group were
A53T and control mice stayed on the rotating rod (n = 9 per group).
nd control mice (n = 9 per group). d and e Effects of EA on the
Effects of EA on the regularity index of A53T and control (n = 6 per
urveyed. Data are expressed as means ± SEM. ***P < 0.001 vs. nTg
Deng et al. Journal of Neuroinflammation  (2015) 12:103 Page 6 of 14of the motor disability after 2 months might be due to
substantial expression of α-syn in astrocytes. EA by tar-
geting overexpressed α-syn could therefore exert its
therapeutic effects (see below).
EA alleviated astrocytic α-syn expression in A53T mice
To observe the influence of EA on the aggregation of
α-syn, expression of A53T α-syn in the midbrain and
striatum was investigated in this study. Abundant ex-
pression of A53T α-syn was seen in the GFAP-positive
astrocytes as demonstrated by co-staining of α-syn with
GFAP in the SN (Fig. 3a). Western blots also showed
that the level of exogenous α-syn was gradually in-
creased in the midbrain and striatum over different time
points (1 month, 2 month, and symptomatic time) in
A53T mice, while α-syn immunoreactivity was absent in
these regions in nTg control mice (Fig. 3b, c). After 4
weeks of 100 Hz EA treatment, the level of α-syn pro-
teins in the midbrain of A53T mice became significantly
lower than that in untreated A53T mice (Fig. 4a). SimilarFig. 3 Expression of α-syn in astrocytes in the SN and striatum of A53T mic
α-syn (red) and GFAP (green) costaining in the SN of A53T mice. The α-syn
c Immunoblot analysis of expression of α-syn proteins in the midbrain and
the quantified data. A53T mice were sacrificed for subsequent immunoblot a
the symptomatic A53T mice. Data are expressed as means ± SEM (n = 4 per gresults were observed in the striatum (Fig. 4b). In con-
trast to proteins, EA did not affect α-syn mRNA expres-
sion in the midbrain (Fig. 4c) and striatum (Fig. 4d). In
nTg mice with or without EA, no α-syn expression at
either protein or mRNA levels was observed. These data
suggest that 100 Hz EA, while it did not affect A53T
α-syn transcription, downregulated α-syn protein ex-
pression in the midbrain, and striatum of mutant mice.
EA attenuated astrogliosis in A53T mice
Astrocytic expression of A53T α-syn appeared to disrupt
multiple normal functions of astrocytes, resulting in se-
vere astrogliosis throughout the brain and spinal cord
[15]. We then assessed the rate of astrogliosis by analyz-
ing expression of GFAP in A53T mice. Immunofluores-
cent staining revealed a larger number of GFAP-positive
astrocytes in the SN of A53T mice (Fig. 5a). EA (100
Hz) decreased the number of GFAP-immunoreactive as-
trocytes (Fig. 5a). Similarly, in immunoblot assays, EA
effectively alleviated the excessive expression of GFAP ine. a Representative immunofluorescent photomicrographs showing
immunoreactivity was restricted to GFAP-expressing astrocytes. b and
striatum of A53T mice. Representative immunoblots are shown above
nalysis at 1 or 2 months after the birth or at the paralysis development in
roup). ***P < 0.001 vs. 1 or 2 months
Fig. 4 EA decreased exogenous α-syn expression in the midbrain and striatum of A53T mice. a and b Effects of EA on α-syn protein expression
in the midbrain (a) and striatum (b) of A53T and nTg control mice. Representative immunoblots are shown above the quantified data. Note
that expression level of α-syn proteins in both the midbrain and striatum was markedly reduced by EA. c and d Effects of EA on α-syn mRNA
expression in the midbrain (c) and striatum (d) of A53T and nTg control mice. The α-syn mRNA level in midbrain and striatal tissue was detected
by real-time PCR. Data are expressed as means ± SEM (n = 4 per group). #P < 0.05, ##P < 0.01 vs. A53T group
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GFAP in the EA-treated A53T mice still remained
higher than that seen in control nTg mice. In addition,
GFAP mRNA expression was probed using quantitative
RT-PCR. We found that GFAP mRNA expression was
elevated in the midbrain (Fig. 5c) and striatum (Fig. 5d)
of A53T mice. However, unlike GFAP proteins, GFAP
mRNA levels in these regions remained at a higher con-
trol level after EA treatment. The fact that EA limited
the protein although no mRNA expression of GFAP in
astrocytes of A53T mice indicates that EA may primarily
inhibit reactive astrogliosis.
EA alleviated microglial activation and inflammation
responses in A53T mice
Whether EA affects microglial activation and inflamma-
tory responses was investigated in A53T mice. Activatedmicroglia was observed in the SN of A53T mice, as evi-
denced by increased Iba-1 immunoreactivity and by the
appearance of microglia clusters (Fig. 6a). EA stimula-
tion effectively reduced the intensity of Iba-1 immuno-
staining and the clusters of activated microglia. Levels of
inflammatory cytokines, such as TNF-α and IL-1β
closely correlating with the presence of activated micro-
glia, were quantified by ELISA in the SN and striatum.
A53T mice exhibited a higher level of TNF-α expression
in the midbrain and striatum, which was blocked by EA
treatment (Fig. 6b). Similar results were seen for IL-1β
expression in the striatum (Fig. 6c). Regarding IL-1β
expression in the midbrain, an insignificant increase in
IL-1β levels was observed in A53T mice after EA treat-
ment. These results demonstrate the ability of EA to in-
hibit microglial activation and neuroinflammation induced
by exogenous expression of A53T α-syn in astrocytes.
Fig. 5 EA reduced the astrogliosis in the midbrain of A53T mice. a Immunofluorescent images illustrating effects of EA on GFAP immunostaining
in the SN of A53T and control nTg mice. GFAP-containing astrocytes were visualized by GFAP immunostaining. b Immunoblots illustrating the
effects of EA on GFAP protein expression in the midbrain. Representative immunoblots are shown above the quantified data. c and d Effects of
EA on GFAP mRNA expression in the midbrain (c) and striatum (d) of A53T and control nTg mice. α-syn mRNAs were detected determined by
quantitative real-time PCR. Data are expressed by means ± SEM (n = 4 per group). **P < 0.01, ***P < 0.001 vs. nTg group. #P < 0.05, ###P < 0.001
vs. A53T group
Fig. 6 EA inhibited microglia activation and inflammatory responses in A53T mice. a Immunofluorescent images illustrating effects of EA on Iba1
immunostaining in the SN of A53T and nTg control mice. Iba1-containing microglia was visualized by Iba-1 immunostaining. b and c Effects of
EA on TNF-α (b) and IL-1β (c) expression in the midbrain (upper panels) and striatum (lower panels) of A53T mice and nTg control mice. TNF-α
and IL-1β protein levels were assessed by ELISA. Note that EA significantly reduced TNF-α expression in the midbrain and striatum and IL-1β
expression in the striatum of A53T mice. Data are expressed as means ± SEM. *P < 0.05, **P < 0.01 vs. nTg group. #P < 0.05, ###P < 0.001 vs.
A53T group
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of spinal motor neurons in A53T mice
To determine whether EA prevents neuronal loss in the
midbrain of A53T mice, we monitored changes in the
number of TH-positive dopaminergic neurons in the SNpc
using an unbiased stereological method. As expected, the
number of TH-positive neurons was decreased by 62.4 % in
the SNpc of A53T mice compared to nTg mice (Fig. 7a, b).Fig. 7 EA protected DA neurons in the SNpc and motor neurons in the sp
photomicrographs showing TH immunostainings in the SNpc of A53T and nTg
of TH-positive dopaminergic neurons in the SNpc of A53T and nTg contr
stereological analysis. c Effects of EA on the striatal DA content. Striatal D
in the midbrain. TH proteins were detected by immunoblot analysis. Rep
e Representative images show NeuN staining in the ventral horn of lumb
EA+ A53T mice. Scale bar, 200 μm. f These images are the enlarged view
expressed by means ± SEM (n = 5 per group). *P < 0.05, **P < 0.01, ***PEA treatment significantly rescued the loss of neurons
(Fig. 7a, b). A significant reduction of DA content (72.5 %
of control) was seen in the striatum of A53T mice as de-
tected by HPLC assays (Fig. 7c). EA stimulation partially re-
versed this reduction. In addition, reduced TH protein
expression in the midbrain of mutant mice was partially re-
covered by EA (Fig. 7d). Thus, EA promotes survival of
dopaminergic neurons in the midbrain of A53T mice.inal cord in A53T mice. a Representative immunohistochemical
control mice following EA treatment. Scale bar, 200 μm. b Quantification
ol mice following EA treatment. The TH neurons were counted by
A levels were assessed by HPLC. d Effects of EA on TH protein levels
resentative immunoblots are shown above the quantified data.
ar spinal cord of control nTg mice, EA+ nTg mice, A53T mice, and
s from areas indicated in the (e). Scale bar, 200 μm. Data are
< 0.001 vs. nTg group. #P < 0.05, ##P < 0.01 vs. A53T group
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were investigated by the immunostaining of NeuN. Cell
bodies and dendrites of large motor neurons in the ven-
tral horn were clearly stained in control mice. The dens-
ity of immunostaining in motor neurons was reduced in
both the cervical and lumber spinal cord of A53T mice
compared to control mice (Fig. 7e, f ). EA prevented the
loss of these neurons in the spinal cord.
EA modulated expression of Nrf2, HO-1, and GCLM
proteins in A53T mice
It is well known that Nrf2 suppresses neurodegeneration
via a mechanism involving the inhibition of oxidative
stress and gliosis. In A53T mice, Nrf2 protein levels were
dramatically reduced in the midbrain and striatum com-
pared to nTg mice (Fig. 8a, b). EA stimulation substan-
tially increased Nrf2 proteins in the midbrain to a level
higher than that in nTg control mice (Fig. 8a). EA alsoFig. 8 EA increased expression of Nrf2 and its downstream factors in the m
HO-1 and GCLM protein expression in the midbrain (a) and striatum (b). Re
that EA significantly reversed the reduction of three proteins in A53T mice.
midbrain. EA produced the similar recovery of reduced Nrf2 and HO-1 mRN
(n = 4 per group). *P < 0.05 vs. nTg group. ##P < 0.01, ###P < 0.001vs. A53increased Nrf2 expression in the striatum (Fig. 8b). Mean-
while, EA markedly elevated the Nrf2 mRNA level in the
midbrain of A53T mice compared to untreated-mice
(Fig. 8c). Similarly, EA treatment significantly increased
HO-1 protein expression in the midbrain and striatum
and GCLM expression in the midbrain (Fig. 8a, b). At the
mRNA level, EA upregulated HO-1 and GCLM mRNA
expression in the midbrain (Fig. 8c). These results indicate
the ability of EA to upregulate expression of these proteins
in both the midbrain and striatum of A53T mice.
Discussion
The principal finding of the present study was that high
frequency EA stimulation alleviated motor impairments
and delayed the progression of disease in A53T α-syn
transgenic mice. EA seems to be anti-inflammatory since
it inhibited microglial activation, reduced cytokine pro-
duction, and preserved the moderate astrogliosis in theidbrain and striatum of A53T mice. a and b Effects of EA on Nrf2,
presentative immunoblots are shown above the quantified data. Note
c Effects of EA on Nrf2, HO-1, and GCLM mRNA expression in the
A expression in A53T mice. Data are expressed by means ± SEM
T group
Deng et al. Journal of Neuroinflammation  (2015) 12:103 Page 11 of 14brain. EA also increased expression of Nrf2-dependent
antioxidants and prevented the loss of midbrain dopa-
minergic neurons and motor neurons in the spinal cord.
These effects establish EA as a useful tool for treating
neuroinflammatory disorders.
EA modulated α-syn pathology and alleviated motor
disability in A53T mice
According to Braak et al. [33], α-syn deposition occurs
at the earliest stage of PD without neuronal loss or clin-
ical symptoms. The deposition takes place in both astro-
cytes and microglia [10], which eventually leads to the
characteristic behavioral and pathological features of PD
[34]. In transgenic mice, aggregated and truncated forms
of α-syn were significantly increased in the brain [15],
which could impair the normal function of astrocytes
and initiate the downstream pathogenic events [35]. In
this study, we observed an accumulation of α-syn pro-
teins in the midbrain and striatum of symptomatic
A53T mice. Interestingly, α-syn expression was subject
to the EA modulation. After prolonged EA stimulation,
the amount of α-syn proteins in the midbrain and stri-
atum was reduced. While α-syn protein levels were re-
duced, α-syn mRNAs were not affected by EA. This
seems to indicate that EA may primarily affect posttran-
scriptional steps, such as translation, aggregation, deg-
radation, and/or propagation, to alter α-syn protein
expression. How EA regulates α-syn expression is un-
clear. It has been found that EA increased ubiquitin C
terminal hydrolase-L1 (UCH-L1) and ubiquitin activat-
ing enzyme-1 (UBE1) expression in the SN, which led to
a reduction of α-syn expression and toxicity [36]. Thus,
EA likely modulates α-syn expression via a UCH-L1/
UBE1-dependent mechanism. In addition, apolipopro-
tein D, a lipocalin involved in lipid metabolism, is consti-
tutively expressed in astrocytes [37]. Due to structural
similarities, lipocalins act as autocrine factors to interact
with α-syn and reduce reactive astrogliosis [37]. Thus, it
is possible that EA could modulate the substances such
as lipocalins to indirectly influence α-syn and astrocytes.
The expression level of exogenous A53T α-syn deter-
mines the onset and severity of behavioral abnormalities
in these mutant mice. It has been found that the early-
onset paralysis occurred in A53T-E2 mice (the high ex-
pression of α-syn in astrocytes), and however, there were
no obvious behavior abnormalities in A53T-A8 mice
(the low expression line) [15]. Thus, the improving effect
of EA on motor behaviors may be derived from the
regulation of α-syn expression in A53T mice.
In A53T mice, excessive A53T α-syn in astrocytes dis-
rupted the normal function of astrocytes, leading to in-
flammation and microglial activation in the midbrain and
spinal cord. Activated microglia then trigger the loss of
neuron, which may contribute to the movement disability.A recent study has found that conditional expression of
tet-regulated A53T missense mutation α-syn in the mid-
brain dopaminergic neurons caused key motor and patho-
logical phenotypes of PD [38], although not paralysis. This
indicates that the paralysis phenotype results from the loss
of motor neurons in the spinal cord. In this study, EA was
effective in alleviating both PD-like motor behaviors and
paralysis in A53T mice, which corresponds well with the
EA effect in preventing the loss of dopaminergic neurons
in the midbrain and motor neurons in the spinal cord.
Taken together, EA reverses the loss of neurons in the
midbrain and spinal cord to improve respective motor
activities.
Roles of reactive astrogliosis in PD and EA effects
Severe reactive astrogliosis interferes with the normal
function of astrocytes that is critical for maintaining the
integrity of blood–brain barrier (BBB) and for regulating
the homeostasis of glutamate transporters [15]. While se-
vere astrogliosis is disadvantageous, reactive astrocytes
also play a compensatory role. This was evidenced by the
finding that selective and conditional ablation of reactive
astrocytes caused greater neuronal and oligodendrocyte
degeneration, greater inflammatory responses, less recov-
ery of the BBB, and more severe functional deficits in a
spinal cord injury transgenic mouse [39]. Moreover, react-
ive astrocytes promoted dopaminergic neuronal recovery
[40]. In our studies, A53T mice showed severe astrogliosis
as evidenced by a substantial increase in the number of
GFAP-positive astrocytes and GFAP protein overexpres-
sion in the SN. EA was able to partially reduce astrogliosis.
However, it is important to note that EA did not com-
pletely abolish reactive astrogliosis. As a matter of fact, a
moderate and significant degree of reactive astrogliosis
remained following EA stimulation. Thus, EA seems to
tune down the excessive reactive astrogliosis and at the
same time preserve moderate reactive astrogliosis. This
fine adjustment is useful to preserve a certain amount of
reactive astrogliosis beneficial for neuronal survival.
The functional role of reactive astrocytes in regulating
neuroinflammation is noteworthy [41, 10]. In A53T mice,
reactive astrocytes are major cells that recruit and trigger
the activation of microglia and increase expression of pro-
inflammatory cytokines such as TNF-α and IL-1β in the
midbrain and striatum. By activating microglia and releas-
ing cytokines, astrocytes are linked to the loss of dopa-
mine neurons and motor symptoms of PD. In support of
this, we found that the number of activated microglia was
enhanced in the SN of A53T mice. Parallel increases in
pro-inflammatory cytokines (TNF-α and IL-1β) were also
observed in the midbrain and striatum. Meanwhile, EA
inhibited microglial activation and inflammatory cyto-
kine expression. These results suggest that EA may
exert its alleviating effects on PD symptoms through a
Deng et al. Journal of Neuroinflammation  (2015) 12:103 Page 12 of 14mechanism involving the inhibition of microglia activa-
tion and microglia-mediated inflammatory reactions.
Of note, microglia activation is classified into two major
phenotypes: detrimental M1 (classical activation) and
beneficial M2 (alternative activation) phenotypes [42].
Astrocytic expression of A53Tcertainly evoked M1 micro-
glial activation at the symptomatic stage. EA effectively
reduced the activation of microglia and expression of M1-
related inflammatory cytokines, such as TNF-α and IL-1β.
Little is known about the activation of the M2 phenotype
in the PD pathogenesis [43]. Recently, an epigenetic study
has suggested that histone H3K27me3 demethylase Jmjd3
may facilitate the switch of microglia phenotypes from M2
to M1 polarization [44]. Therefore, it will be interesting to
know whether EA helps switch M1/M2 phenotypes in the
future studies.
Nrf2 signal pathways in PD and EA effects
An important anti-oxidant and anti-inflammatory mech-
anism involves the Nrf2-ARE pathway. Selective Nrf2
expression in astrocytes is sufficient to prevent the 1-
methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced loss
of dopaminergic neurons [40]. In response to exogenously
added α-syn, Nrf2−/− mice showed an exacerbated loss of
nigral dopaminergic neurons and increased neuroinflam-
mation and gliosis at the early PD stage [28]. Therefore,
the activation of the Nrf2-ARE pathway is of a neuropro-
tective nature [45]. Consistent with this, Nrf2 modulated
microglial activation to produce anti-inflammatory re-
sponses [46]. In contrast, impaired Nrf2 responses corre-
lated with a shift in the microglial activation profile,
towards an increased production of proinflammatory
markers (IL-6, IL-1β, iNOS, and NF-κB). The relevance of
Nrf2-regulated genes in inflammation has also been iden-
tified in postmortem biopsies of PD patients. An increase
in HO-1 expression in glial cells has been revealed, which
however was insufficient to elicit an effective protection of
SN neurons [45]. In this study, we observed lower expres-
sion of Nrf2 and its downstream molecules (HO-1 and
GCLM) in the midbrain and striatum of A53T mice. EA
was able to upregulate expression of these proteins. Of
note, the Nrf2 protection is not restricted to α-syn tox-
icity. In fact, Nrf2 plays a role in overall neuronal degener-
ation seen in oxidative stress, environmental toxins,
proteinopathy, and inflammation [45]. Thus, Nrf2 repre-
sents a common site for developing pharmacotherapies to
treat a wide range of neurodegenerative diseases, includ-
ing PD, Alzheimer’s disease, and Huntington’s disease.
Potential anti-inflammation pathways of EA
Neural mechanisms underlying the EA effect have long
been investigated [24, 47, 25]. Recent studies suggest a
neural-immune model. EA is typically applied to the
deep tissue enriched with sensory innervations [48].Sensory signals induced by EA stimulation alter the im-
mune system to dynamically control immunity activity
[49]. Indeed, EA stimulation at the ST36 Zusanli acu-
point decreased the lipopolysaccharide-induced inflam-
matory cytokines, including TNF, monocyte chemotactic
protein-1, IL-6, and interferon-γ [24]. However, the anti-
inflammatory action of EA was abolished by surgical sec-
tioning of the sciatic nerve. Conversely, direct stimulation
of the sciatic nerve mimicked the anti-inflammatory effect
of EA [24]. Thus, it appears that EA stimulation of the
acupoints on the hind-limb acts as an effective vagal
stimulation, which can control inflammation. However,
the exact anatomical pathways connecting EA signals to
the immune system are poorly understood [50]. Future
studies will explore those pathways in details.
Conclusions
Our results demonstrate that EA effectively increased sur-
vival of A53T mice, decreased non-neuronal expression of
α-syn, and inhibited inflammatory responses. Meanwhile,
EA preserved the moderate astrogliosis, protected the
dopaminergic neurons, and alleviated motor impairments.
These data indicate a causative relationship between glial
α-syn-mediated inflammation responses and chronic
dopaminergic neurodegeneration. Moreover, EA by inhi-
biting degenerative processes at multiple levels has po-
tential to be a useful tool for treating neurodegenerative
diseases.
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